Hallmarks and correlates of effective adoptive cell immunotherapy for cancer
Researchers map how immune cell therapies work against cancer and identify markers that predict which patients will respond best.
The NCI Surgery Branch (Rosenberg group) provides a comprehensive review of adoptive cell transfer immunotherapy, covering TIL and TCR-T clinical outcomes, emerging correlates of response including CD39-expressing tumor-specific T cells, and multi-disciplinary strategies for next-generation ACT design. This authoritative synthesis from the pioneers of the field serves as a roadmap for translational development of ACT against solid tumors.
What the study was
- Study design
- Comprehensive expert review
- Population
- Patients with metastatic solid tumors (melanoma, breast, GI, sarcoma, lung) treated with ACT
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Reviews Immunology
Why it surfaced
Landmark review from Steven Rosenberg's NCI group in Nature Reviews Immunology synthesizes the ACT field following FDA approvals of lifileucel and afami-cel; identifies key correlates of response and next-generation engineering strategies. Exceptionally high clinical and research translation value for the immunotherapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.